Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190335 | 0.85 | MAPK14 (0.56) | MAPK14KDM4E | |
| SCHEMBL5481416 | 0.84 | MAPK14 (0.53) | MAPK14LMNAKDM4EPTGES | |
| Bromide SCHEMBL11178448 | 0.84 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL5485402 | 0.81 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL9370221 | 0.81 | KDM4E (0.62) | KDM4EPTGES | |
| SCHEMBL5452001 | 0.80 | KDM4E (0.45) | MAPK14LMNAKDM4EPTGES | |
| SCHEMBL5434845 | 0.80 | MAPK14 (0.49) | MAPK14LMNAKDM4EGSK3BEGFR | |
| SCHEMBL3174806 | 0.78 | KDM4E (0.65) | LMNAKDM4EPTGES | |
| SCHEMBL5452003 | 0.77 | PTGES (0.53) | LMNAKDM4EEGFRPTGES | |
| SCHEMBL11172466 | 0.75 | MAPK14 (0.57) | MAPK14LMNAKDM4EGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | BEIERSDORF, AG | 2007-08-09 | — | — | US | disclosed |
| US-7223781-B2 | 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040116695-A1 | 2-Mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | PTGS2, PTGES2, DHFR | MAPK14 2955/4885LMNA 4883/4885KDM4E 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.